Wuxi Tushen Zhihe Artificial Intelligence Technology Co., Ltd. has completed both its Pre-A and Pre-A+ financing rounds in quick succession, raising a combined total of hundreds of millions of yuan. The Pre-A round was led by Shanghai Sci-Tech Group with participation from several institutions, while the Pre-A+ round drew joint investment from Jinding Capital, MegaRobo Technologies, Zero2IPO Holdings, and others, with Kaicheng Capital serving as long-term exclusive financial advisor. The proceeds will be used to accelerate the advancement of the company's self-developed pipelines, upgrade its one-stop AI drug design platform, and strengthen team operations and market expansion. Founded in 2023, Tushen Zhihe focuses on AI-driven protein design. Its core team brings extensive experience at the intersection of AI and the life sciences, and has independently built a technology system and the ToursynClaw platform that cover the entire protein design workflow. This has established a full dry-wet closed loop capable of rapidly identifying candidate proteins with high activity and stability, significantly shortening the drug development cycle. The company's founder, its investors, and the financial advisor each commented on the financing and the broader industry landscape.